Emerging Talent
Early Careers
Search
Clinical Trials
Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Health disparities in Black and African Americans
Addressing social determinants of health in cardio-kidney-metabolic care
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Welcome to Animal Health Partnering
Welcome to Animal Health Partnering
Vaccines
Vaccines
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD
Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.
Our Partnering Approach
Our Partnering Approach
About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Cardiologists at the Heart of Cardio-Renal-Metabolic Care
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Management Rotation | Academic Programs
Management Rotation Program
Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
Real-world study shows sequencing of Gilotrif
new_health_insurance_marketplace_coverage_options_and_your_health_coverage.pdf
Prescription digital therapeutics and mental health care
us-randd-key-fact.pdf
STAR Interview Tips and Behavioral Interviews
Dr. Anna Dieckmann and Dr. Lorenz Maier
Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Employees join #stayhomeandfoster movement
Employees join #stayhomeandfoster movement
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.